Merck, Inc.
🇵🇭Philippines
A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)
Phase 4
Completed
- Conditions
- Opiate DependenceDrug DependenceSubstance Dependence
- Interventions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 188
- Registration Number
- NCT00604188
Bunionectomy Study (0000-063)
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00601458
Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)
Phase 1
Completed
- Conditions
- Non-small Cell Lung CancerCarcinoma
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00599755
Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)
Phase 3
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: diquafosol tetrasodium Ophthalmic Solution, 2%Drug: Non-preserved saline solution (Placebo)
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00600288
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00591409
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00591786
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
Phase 4
Completed
- Conditions
- Bacterial InfectionsEye InfectionsCataract Extraction
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT00575380
- Locations
- 🇺🇸
Eye Care Specialists, Kingston, Pennsylvania, United States
🇺🇸Ophthalmic Consultants of Long Island, Rockville Centre, New York, United States
🇺🇸Ophthalmology Associates, St. Louis, Missouri, United States
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
Phase 4
Completed
- Conditions
- Bacterial InfectionsEye Infections
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00575367
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
Phase 2
Completed
- Conditions
- Staphylococcus Aureus Infection
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00572910
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
Phase 1
Completed
- Conditions
- Diabetic NeuropathyPainful Small-Fiber NeuropathyIdiopathic Distal Sensory PolyneuropathyNeuralgia, Postherpetic
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 104
- Registration Number
- NCT00570310
© Copyright 2025. All Rights Reserved by MedPath